Canakinumab in gout

被引:30
作者
Schlesinger, Naomi [1 ]
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Div Rheumatol, New Brunswick, NJ 08903 USA
关键词
canakinumab; gout; interleukin-1 beta inhibitor; DOUBLE-BLIND; CONTROLLED-TRIAL; PHASE-II; ARTHRITIS; MANAGEMENT; FLARES; INDOMETHACIN; MULTICENTER; ETORICOXIB; COLCHICINE;
D O I
10.1517/14712598.2012.705825
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 090105 [作物生产系统与生态工程];
摘要
Introduction: Gout is a painful inflammatory arthritis with a prevalence of approximately 4% in the United States, affecting an estimated 8.3 million adults. The past 20 years have shown significant increases in the number of patients with gout and its incidence may still be increasing. Current treatment options to control the pain and inflammation of acute gout include nonsteroidal anti-inflammatory drugs, colchicine and corticosteroids, although patients are often unresponsive to, intolerant of, or have contraindications for, these therapies. Additional treatment options are therefore needed for this population with difficult-to-treat gout. Areas covered: Currently available and investigational anti-inflammatory agents for acute and chronic gout will briefly be reviewed. Canakinumab, a fully human monoclonal anti-interleukin (IL)-1 beta antibody that selectively blocks IL-1 beta and that is being investigated for the treatment of gout, will be discussed in greater detail. Expert opinion: Canakinumab has been found to be superior to triamcinolone acetonide in acute gout and to colchicine in gout attack prophylaxis in reducing pain and risk of new gout attacks. Canakinumab's long half-life contributes to its prolonged anti-inflammatory effects.
引用
收藏
页码:1265 / 1275
页数:11
相关论文
共 30 条
[1]
DOES COLCHICINE WORK - THE RESULTS OF THE 1ST CONTROLLED-STUDY IN ACUTE GOUT [J].
AHERN, MJ ;
REID, C ;
GORDON, TP ;
MCCREDIE, M ;
BROOKS, PM ;
JONES, M .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1987, 17 (03) :301-304
[2]
[Anonymous], 2009, KIN R AN PACK INS
[3]
[Anonymous], 2011, IL R CAN PACK INS
[4]
[Anonymous], 2011, COLCR R COLCH PACK I
[5]
[Anonymous], 2010, ARC R RIL PACK INS
[6]
Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody [J].
Abhijit Chakraborty ;
Stacey Tannenbaum ;
Christiane Rordorf ;
Philip J. Lowe ;
David Floch ;
Hermann Gram ;
Sandip Roy .
Clinical Pharmacokinetics, 2012, 51 (6) :e1-e18
[7]
The inflammatory process of gout and its treatment [J].
Cronstein, Bruce N. ;
Terkeltaub, Robert .
ARTHRITIS RESEARCH & THERAPY, 2006, 8 (Suppl 1)
[8]
Eggebeen AT, 2007, AM FAM PHYSICIAN, V76, p[801, 811]
[9]
Fam A G, 1997, J Clin Rheumatol, V3, P35, DOI 10.1097/00124743-199702000-00007
[10]
British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout [J].
Jordan, Kelsey M. ;
Cameron, J. Stewart ;
Snaith, Michael ;
Zhang, Weiya ;
Doherty, Michael ;
Seckl, Jonathan R. ;
Hingoranis, Aroon ;
Jaques, Richard ;
Nuki, George .
RHEUMATOLOGY, 2007, 46 (08) :1372-1374